The Growing Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) Would Have a Significant Impact on the Liver Disease Treatment Market During the Forecast Period of 2023-2028

The Liver Disease Treatment Market is estimated to reach $31.7 billion by 2028, growing at a CAGR of 11.4% over the forecast period of 2023–2028. The excessive buildup of extra fat in the liver is a typical symptom of liver disease and, in particular, non-alcoholic fatty liver disease (NAFLD). In many regions, NAFLD is recognized as the primary contributor to chronic liver disease. According to the American College of Cardiology (ACC), around 25% of people are thought to have NAFLD worldwide, with South Asia having the highest prevalence rate (33%). The prevalence of NAFLD is thought to be 30% in the U.S. in 2022. As a result, healthcare sectors are developing creative and appealing programs to combat liver illnesses. Such programs are primarily focused on a number of issues, such as the early diagnosis and management of NAFLD and the development of a healthcare system for the control, detection and treatment of NAFLD. Such government actions could boost the market for treating liver disease within the anticipated time frame. North America held the largest market share of 32% in 2022 because of the advancements in medicine and the healthcare system. Asia-Pacific is anticipated to grow the fastest during the forecast period of 2023–2028, due to the growing prevalence of liver diseases in the region as a result of changing lifestyles.

Growth in Hepatitis Infections is Set to Increase the Incidence of Liver Cirrhosis:

Liver inflammation is brought on by the viral infection recognized as hepatitis. The most prevalent viruses that result in cirrhosis worldwide are hepatitis B and C. Although less frequently, hepatitis A and D are also known to cause significant liver scarring. According to the National Library of Medicine (NLM), it is estimated that liver disease causes around 2 million fatalities annually around the world, including 1 million deaths from cirrhosis-related complications and 1 million deaths from viral hepatitis and hepatocellular cancer. 

In May 2020, Enanta Pharmaceuticals Inc. revealed the topline findings of their INTREPID Phase 2 research of EDP-305, a farnesoid X receptor (FXR), in patients with primary biliary cholangitis. Over the years, companies have mainly focused on developing various treatments for liver disease that have high acceptance across the globe. This has helped them augment their respective positions in the market. The increase in awareness of liver diseases and the considerable R&D investments are the major factors set to buoy the global nutritional premix market during 2023–2028.

In September 2021, the U.S. Food and Drug Administration (FDA) approved the oral solution LIVMARLI (malalixibat) for the management of cholestatic pruritis in individuals with Allagile Syndrome (ALGS) aged one year and older. This approval was given to Mirum Pharmaceuticals, Inc., a pioneer in the field of uncommon liver disease.

The major companies in the Liver Disease Treatment Market include Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences, Alnylam Pharmaceuticals Inc., AbbVie Inc., Zydus Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Mirum Pharmaceuticals and Others.